These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24219003)

  • 21. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
    Holst JJ; Deacon CF
    Curr Opin Pharmacol; 2004 Dec; 4(6):589-96. PubMed ID: 15525549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
    Juillerat-Jeanneret L
    J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis.
    Aoyama M; Kawase H; Bando YK; Monji A; Murohara T
    Circ Heart Fail; 2016 Jan; 9(1):e002081. PubMed ID: 26721911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel aspects of cellular action of dipeptidyl peptidase IV/CD26.
    Ansorge S; Nordhoff K; Bank U; Heimburg A; Julius H; Breyer D; Thielitz A; Reinhold D; Täger M
    Biol Chem; 2011 Mar; 392(3):153-68. PubMed ID: 21194362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.
    Reinhold D; Bank U; Bühling F; Kähne T; Kunt D; Faust J; Neubert K; Ansorge S
    Immunobiology; 1994 Dec; 192(1-2):121-36. PubMed ID: 7750986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Expression and Enzymatic Activity of DPPIV/CD26 Affects Migration Ability of Cervical Carcinoma Cells.
    Beckenkamp A; Willig JB; Santana DB; Nascimento J; Paccez JD; Zerbini LF; Bruno AN; Pilger DA; Wink MR; Buffon A
    PLoS One; 2015; 10(7):e0134305. PubMed ID: 26222679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dipeptidyl Peptidase-4 Regulates Hematopoietic Stem Cell Activation in Response to Chronic Stress.
    Zhu E; Hu L; Wu H; Piao L; Zhao G; Inoue A; Kim W; Yu C; Xu W; Bando YK; Li X; Lei Y; Hao CN; Takeshita K; Kim WS; Okumura K; Murohara T; Kuzuya M; Cheng XW
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28710180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
    Balakumar P; Dhanaraj SA
    Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD26/DPPIV inhibition alters the expression of immune response-related genes in the thymi of NOD mice.
    Julián MT; Alonso N; Colobran R; Sánchez A; Miñarro A; Pujol-Autonell I; Carrascal J; Rodríguez-Fernández S; Ampudia RM; Vives-Pi M; Puig-Domingo M
    Mol Cell Endocrinol; 2016 May; 426():101-12. PubMed ID: 26911933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Winkler G
    Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
    Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
    Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.
    Deacon CF
    Peptides; 2018 Feb; 100():150-157. PubMed ID: 29412814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
    Davidson MH
    Postgrad Med; 2014 May; 126(3):56-65. PubMed ID: 24918792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of glucagon-like peptide 1; what to measure?
    Heijboer AC; Frans A; Lomecky M; Blankenstein MA
    Clin Chim Acta; 2011 Jun; 412(13-14):1191-4. PubMed ID: 21414305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD26 costimulatory blockade improves lung allograft rejection and is associated with enhanced interleukin-10 expression.
    Yamada Y; Jang JH; De Meester I; Baerts L; Vliegen G; Inci I; Yoshino I; Weder W; Jungraithmayr W
    J Heart Lung Transplant; 2016 Apr; 35(4):508-17. PubMed ID: 26755203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages.
    Hiromura M; Nohtomi K; Mori Y; Kataoka H; Sugano M; Ohnuma K; Kuwata H; Hirano T
    Biochem Biophys Res Commun; 2018 Jan; 495(1):223-229. PubMed ID: 29113797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
    Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
    Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
    Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.